10.11.19 | Policy
SWHR’s Health Care Value Assessment Principles
The U.S. health care system is undergoing transformative changes in the way that it delivers and pays for care. The […]
7.24.19 | Policy
SWHR Letter in Support of PRGLAC Task Force
In a letter to the Secretary of Health and Human Services, SWHR expressed its concerns about the future status of […]
7.8.19 | Policy
SWHR Praises FDA Draft Guidance on Lactation Study Design
SWHR sent comments to the Food and Drug Administration (FDA) regarding the agency’s new draft guidance on pre- or post-market […]
7.8.19 | Policy
SWHR Comments on FDA Draft Guidance on Post-Approval Pregnancy Safety Studies
SWHR provided comments to the Food and Drug Administration (FDA) on its recently released draft guidance pertaining pregnancy safety study […]
6.10.19 | Policy
SWHR Provides Input on ICER Value Assessment Framework
SWHR provided input to the Institute for Clinical and Economic Review (ICER) on the 2020 update to its value assessment […]
4.15.19 | Policy
SWHR Calls for Robust NIH Funding for FY 2020
SWHR sent letters to the Senate and House subcommittees that oversee funding for the National Institutes of Health (NIH) urging […]
3.19.19 | Policy
SWHR Comments on HHS Task Force Pain Management Draft Report
SWHR sent comments to the U.S. Department of Health and Human Services (HHS) in response to the Pain Management Best […]
2.21.19 | Policy
SWHR Principles Addressing Disparities in Drug Development
SWHR developed a set of principles to address diversity within the Patient-Focused Drug Development (PFDD) Program. The PFDD Program, housed […]
2.14.19 | Policy
SWHR Input on NICHD Strategic Plan for FY2020-2024
SWHR sent a letter to Dr. Diana W. Bianchi, Director of the Eunice Kennedy Shriver National Institute of Child Health […]
1.31.19 | Policy
SWHR Expresses Concerns About CMS Guidance for Next Generation Sequencing
In a letter to Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma, SWHR expressed concern about CMS’ new […]
